Hamman-Rich syndrome
Hamman-Rich syndrome is a rare and severe form of interstitial lung disease (ILD) that progresses rapidly, often leading to respiratory failure and death. It is also known as acute interstitial pneumonia (AIP).
Etiology[edit | edit source]
The exact cause of Hamman-Rich syndrome is unknown. However, it is believed to be an inflammatory response to an unknown trigger, possibly a viral infection or an environmental exposure.
Symptoms[edit | edit source]
The symptoms of Hamman-Rich syndrome typically develop rapidly, over a period of days to weeks. They may include shortness of breath, cough, fatigue, weight loss, and fever. As the disease progresses, patients may develop respiratory failure and require mechanical ventilation.
Diagnosis[edit | edit source]
Diagnosis of Hamman-Rich syndrome is challenging due to its rarity and the lack of specific diagnostic criteria. It is often diagnosed based on the clinical presentation and the exclusion of other causes of ILD. Imaging studies, such as a CT scan, may show diffuse ground-glass opacities in the lungs. A lung biopsy may be necessary to confirm the diagnosis.
Treatment[edit | edit source]
There is no specific treatment for Hamman-Rich syndrome. Management is primarily supportive, including oxygen therapy and mechanical ventilation if necessary. Some patients may benefit from corticosteroids or other immunosuppressive drugs, although the evidence for their effectiveness is limited.
Prognosis[edit | edit source]
The prognosis for Hamman-Rich syndrome is generally poor, with a high mortality rate. Many patients die within months of diagnosis due to respiratory failure. However, some patients may have a more indolent course and survive for several years.
See also[edit | edit source]
NIH genetic and rare disease info[edit source]
Hamman-Rich syndrome is a rare disease.
Hamman-Rich syndrome Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD